A 53-year-old woman with B-cell nonHodgkin lymphoma developed MRSA bacteremia complicated by MRSA septic arthritis of the sternoclavicular joint during her chemotherapy. Minimum inhibitory concentrations (MICs) [1] were 2 µg/mL for vancomycin (susceptible), 4 µg/mL for linezolid (susceptible), and 0.5 µg/mL for daptomycin (susceptible). Clinical response to vancomycin was not apparent after 11 weeks of treatment as the patient experienced ongoing sternoclavicular pain and erythema. She was subsequently treated with daptomycin 6 mg/kg/day; the patient was in remission after having completed chemotherapy. The leukocyte count at baseline was 5. A search of Medline, PubMed, Embase, and MedWatch using the search terms daptomycin and neutropenia, daptomycin and cytopenia, and daptomycin and blood dyscrasia did not yield any published cases of neutropenia associated with daptomycin use in animal or human studies. None of the randomized controlled trials involving daptomycin have reported neutropenia as an adverse effect [3] [4] [5] [6] . With this case we would like to alert clinicians that prolonged administration of daptomycin may be associated with neutropenia that was reversible upon drug discontinuation. The frequency and mechanism of this adverse effect are currently unknown. Periodic hematologic assessments in patients receiving daptomycin should be used to monitor for this adverse effect. 
